Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results confirm that CRX-1008 is a potent TTR stabilizer in both plasma and CSF using established ex vivo assays. CRX-1008 normalized TTR concentration in plasma with an overall mean increase in plasma TTR tetramer concentration of 55%.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolcapone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolcapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2018
Lead Product(s) : Tolcapone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Corino Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolcapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Corino Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolcapone
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Hospital Vall d'Hebron
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of SOM0226 in Familial Amyloid Polyneuropathy
Details : Tolcapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyloid Neuropathies, Familial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 16, 2014
Lead Product(s) : Tolcapone
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Vall d'Hebron
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
